Iovance Biotherapeutics clinical trial pipeline

3 trials changed in the last 30 days: 1 stopped, 2 with notable changes, 0 with minor changes only.

1. Stopped

   Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent…Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants

   Trial terminated

   Also in this update: Study completion date changed from estimate of Jul 2028 to Jun 19, 2026; Final enrollment: 5 participants (planned 40)

   Iovance Biotherapeutics, Inc.·Phase 1· NCT06566092· Registry history of NCT06566092 on ClinicalTrials.gov (opens the registry)

   Oct 16, 2026

2. Notable

   Lifileucel (Tumor-infiltrating Lymphocytes) · Advanced Melanoma

   Enrollment reduced: 100 → 24 participants

   Also in this update: Primary completion moved earlier from Dec 2032 to Dec 2027; Study completion moved earlier from Dec 2033 to Jun 2028

   Iovance Biotherapeutics, Inc.·Phase 2· NCT07288203· Registry history of NCT07288203 on ClinicalTrials.gov (opens the registry)

   Oct 1, 2026

3. Notable

   SARATOGA · Lifileucel (Tumor-infiltrating Lymphocytes) · Advanced…SARATOGA · Lifileucel (Tumor-infiltrating Lymphocytes) · Advanced Soft Tissue Sarcoma

   Recruitment opened

   Iovance Biotherapeutics, Inc.·Phase 2· NCT07741877· Registry history of NCT07741877 on ClinicalTrials.gov (opens the registry)

   Oct 9, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.